Editas Medicine, Inc.
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
EDIT$2.51-8.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(1)Financial Statements
Our consolidated financial statements are set forth in Part II, Item 8 “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K and are incorporated herein by reference.
(2)Financial Statement Schedules
Schedules have been omitted since they are either not required or not applicable or the information is otherwise included herein.
(3)Exhibits
The exhibits filed as part of this Annual Report on Form 10-K are listed in the following Exhibit Index.
EXHIBIT INDEX
| Incorporated by Reference | ||||||
|---|---|---|---|---|---|---|
| ExhibitNumber | Description of Exhibit | Form | File No. | Date ofFiling | ExhibitNumber | FiledHerewith |
| 3.1 | Restated Certificate of Incorporation of the Registrant | 8-K | 001-37687 | 6/2/2025 | 3.1 | |
| 3.2 | Amended and Restated By-laws of the Registrant | 8-K | 001-37687 | 12/10/2024 | 3.1 | |
| 4.1 | Specimen Stock Certificate evidencing the shares of common stock | S-1 | 333-208856 | 1/4/2016 | 4.1 | |
| 4.2 | Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 | X | ||||
| 10.1+ | 2013 Stock Incentive Plan, as amended | S-1 | 333-208856 | 1/4/2016 | 10.5 | |
| 10.2+ | Form of Incentive Stock Option Agreement under 2013 Stock Incentive Plan, as amended | S-1 | 333-208856 | 1/4/2016 | 10.6 | |
| 10.3+ | Form of Nonstatutory Stock Option Agreement under 2013 Stock Incentive Plan, as amended | S-1 | 333-208856 | 1/4/2016 | 10.7 | |
| 10.4+ | Form of Early Exercise Nonstatutory Stock Option Agreement under 2013 Stock Incentive Plan, as amended | S-1 | 333-208856 | 1/4/2016 | 10.8 | |
| 10.5+ | Form of Restricted Stock Agreement under 2013 Stock Incentive Plan, as amended | S-1 | 333-208856 | 1/4/2016 | 10.9 | |
| 10.6+ | Amended and Restated 2015 Stock Incentive Plan | 8-K | 333-208856 | 6/2/2025 | 10.1 | |
| 10.7+ | Form of Incentive Stock Option Agreement under 2015 Stock Incentive Plan | 10-K | 001-37687 | 2/28/2024 | 10.7 | |
| 10.8+ | Form of Nonstatutory Stock Option Agreement under 2015 Stock Incentive Plan | 10-K | 001-37687 | 2/28/2024 | 10.8 | |
| 10.9+ | Form of Restricted Stock Agreement under 2015 Stock Incentive Plan | 10-K | 001-37687 | 2/28/2024 | 10.9 | |
| 10.10+ | Form of Restricted Stock Unit Award Agreement under the 2015 Stock Incentive Plan | 10-K | 001-37687 | 2/28/2024 | 10.10 | |
| Incorporated by Reference | ||||||
|---|---|---|---|---|---|---|
| ExhibitNumber | Description of Exhibit | Form | File No. | Date ofFiling | ExhibitNumber | FiledHerewith |
| 10.11+ | Employment Offer Letter, dated April 13, 2022, between the Registrant and Gilmore O’Neill | 10-Q | 001-37687 | 8/3/2022 | 10.1 | |
| 10.12+ | Employment Offer Letter, dated July 7, 2022, between the Registrant and Amy Parison | X | ||||
| 10.13+ | Promotion Letter, dated March 19, 2025, between the Registrant and Amy Parison | X | ||||
| 10.14+ | Employment Offer Letter, dated July 3, 2023, between the Registrant and Linda C. Burkly | 10-Q | 001-37687 | 8/2/2023 | 10.3 | |
| 10.15+ | Form of Inducement Stock Option Agreement for the Registrant’s executive officers | 10-K | 001-37687 | 2/28/2024 | 10.19 | |
| 10.16+ | Form of Inducement Restricted Stock Unit Award Agreement for the Registrant’s executive officers | 10-K | 001-37687 | 2/28/2024 | 10.20 | |
| 10.17† | Amended and Restated Cas9-I License Agreement, dated December 16, 2016, among the Registrant, the President and Fellows of Harvard College (“Harvard”), and the Broad Institute, Inc. (the “Broad”) | 8-K | 001-37687 | 1/23/2017 | 99.2 | |
| 10.18 | Amendment No.1 to Amended and Restated Cas9-I License Agreement, by and among Editas Medicine, Inc., Harvard, and Broad, dated March 3, 2017 | 8-K | 001-37687 | 3/7/2017 | 99.1 | |
| 10.19* | Second Amended and Restated License and Collaboration Agreement, dated November 11, 2019, between the Registrant and Juno Therapeutics, Inc. (“Juno”) | 10-K | 001-37687 | 2/26/2020 | 10.20 | |
| 10.20* | First Amendment, dated March 21, 2024, to the Second Amended and Restated Collaboration and License Agreement, between the Registrant and Juno | 10-Q | 001-37687 | 5/8/2024 | 10.2 | |
| 10.21* | License and Agreement, dated November 11, 2019, between the Registrant and Juno | 10-K | 001-37687 | 2/26/2020 | 10.21 | |
| 10.22† | Sponsored Research Agreement, dated June 7, 2018, between the Registrant and Broad | 10-Q/A | 001-37687 | 10/23/2018 | 10.2 | |
| 10.23* | First Amendment to Sponsored Research Agreement, dated January 11, 2021, between the Registrant and Broad | 10-K | 001-37687 | 2/26/2021 | 10.24 | |
| 10.24* | Purchase and Sale Agreement, dated October 3, 2024, between the Registrant and DRI Healthcare Acquisitions LP | 10.K | 001-37687 | 3/5/2025 | 10.25 | |
| 10.25+ | Summary of Director Compensation Program | X | ||||
| 10.26+ | 2015 Employee Stock Purchase Plan | S-1 | 333-208856 | 1/4/2016 | 10.25 | |
| 10.27+ | Amended and Restated Severance Benefits Plan | 8-K | 001-37687 | 11/22/2023 | 10.1 | |
| 10.28 | Form of Indemnification Agreement between the Registrant and each of its directors and executive officers | S-1 | 333-208856 | 1/4/2016 | 10.28 | |
| 10.29 | Lease Agreement, dated February 12, 2016, between Registrant and ARE-MA Region No. 55 Exchange Holding LLC | 8-K | 001-37687 | 2/19/2016 | 99.1 | |
| Incorporated by Reference | ||||||
|---|---|---|---|---|---|---|
| ExhibitNumber | Description of Exhibit | Form | File No. | Date ofFiling | ExhibitNumber | FiledHerewith |
| 10.30 | First Amendment to Lease Agreement, dated November 15, 2022 between Registrant and ARE-MA Region No. 55, LLC | 10-K | 001-37687 | 2/22/2023 | 10.32 | |
| 10.32† | Cpf1 License Agreement, dated as of December 16, 2016, by and between the Registrant and Broad | 8-K | 001-37687 | 1/23/2017 | 99.1 | |
| 10.32† | Cas9-II License Agreement, dated as of December 16, 2016, by and between the Registrant and Broad | 8-K | 001-37687 | 1/23/2017 | 99.3 | |
| 10.33* | Omnibus Amendment, dated as of January 11, 2021, by and between the Registrant and Broad | 10-K | 001-37687 | 2/26/2021 | 10.32 | |
| 10.34 | Omnibus Amendment, dated as of February 5, 2024, by and among the Registrant, Broad and Harvard | 10-K | 001-37687 | 2/28/2024 | 10.36 | |
| 10.35* | Letter Agreement, dated as of November 18, 2019, by and among, the Registrant, Broad and Harvard | 10-K | 001-37687 | 2/26/2020 | 10.30 | |
| 10.36* | Letter Agreement, dated as of December 16, 2019, by and among, the Registrant, Broad and Harvard | 10-K | 001-37687 | 2/26/2020 | 10.31 | |
| 10.37 | Common Stock Sales Agreement, dated as of May 14, 2021, by and between the Company and TD Securities (USA) LLC, as amended on February 28, 2024 and March 5, 2025 | S-3 | 333-277471 | 3/5/2025 | 1.2 | |
| 19.1 | Insider Trading Policy | 10-K | 001-37687 | 3/5/2025 | 19.1 | |
| 21.1 | Subsidiaries of the Registrant | 10-K | 001-37687 | 2/22/2023 | 21.1 | |
| 23.1 | Consent of Ernst & Young | X | ||||
| 31.1 | Rule 13a-14(a) Certification of Principal Executive Officer | X | ||||
| 31.2 | Rule 13a-14(a) Certification of Principal Financial Officer | X | ||||
| 32.1 | Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. §1350 | X | ||||
| 97 | Dodd-Frank Compensation Recovery Policy | 10-K | 001-37687 | 2/28/2024 | 97 | |
| 101 | The following financial statements from the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statement of Stockholders’ Equity, (v) Consolidated Statements of Cash Flows and (vi) Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags. | |||||
| 104 | The cover page from the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, formatted in Inline XBRL. | |||||
† Confidential treatment has been granted as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission.
*Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. Certain portions of this exhibit have been omitted because they are not material and are information of the type that the registrant customarily and actually treats as private or confidential.
- Management contract or compensatory plan or arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.